Венлафаксин

Quick links

Choose a section

Quick links to important sections

Advertisements

Венлафаксин

Selected form

Advertisements
Advertisements

Overview of Венлафаксин

Quick Facts

Property Description
Active Ingredient Venlafaxine
Pharmacological Class Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Form Tablets; Extended-Release Capsules
Common Use Stabilizing mood and emotional regulation
Origin Synthetic

What is Venlafaxine?

What Type of Medicine is Venlafaxine?

Venlafaxine is a synthetic psychotropic drug classified as a Serotonin-Norepinephrine Reuptake Inhibitor (SNRI). This means it is a dual-acting antidepressant that influences the availability of two major neurotransmitters in the brain.

As an SNRI, Venlafaxine is distinguished from many other common antidepressants because it simultaneously influences both the serotonin and norepinephrine systems. This dual influence is intended to provide a comprehensive approach to emotional balance. The pharmacological profile of Venlafaxine supports its use in conditions that benefit from this dual monoamine reuptake inhibition. This means the medication helps by working on two key chemical pathways in the brain related to mood.

Active Component and Dosage Forms

The sole active ingredient (INN) in the medication is Venlafaxine. It is a single-component drug taken via the oral route.

Venlafaxine is available in standard tablets and extended-release capsules (XR). The extended-release form is a differentiating feature, recognized for improving patient compliance by simplifying the dosing schedule. This specific formulation allows for once-daily dosing due to the slow diffusion of the active substance. For the patient, this means the medication can maintain a consistent effect over 24 hours.

General Purpose of Venlafaxine

The general purpose of Venlafaxine is to assist in the stabilization of a patient's mood and emotional well-being. By rebalancing the key neurotransmitters—serotonin and norepinephrine—Venlafaxine helps restore chemical activity essential for the central nervous system's ability to manage mood and anxiety. This action is designed to correct the chemical imbalances believed to be associated with various mood disorders, often making it a treatment of choice for adults experiencing chronic emotional disturbances.

Advertisements

What side effects are possible with Венлафаксин?

Possible Side Effects and Safety Information

The official safety profile of Venlafaxine is organized by regulatory authorities to classify documented adverse reactions and specific safety constraints, based on regulatory labeling such as the FDA Prescribing Information and the European Summary of Product Characteristics (SmPC).

Frequency-Classified Adverse Reactions

Adverse reactions are categorized by frequency of occurrence observed in clinical trials:

  • Very Common (affecting more than 1 in 10 users): Nausea, dry mouth, and headache.
  • Common (affecting up to 1 in 10 users): Fatigue, dizziness, somnolence, insomnia, constipation, sweating (including night sweats), hypertension, and various forms of sexual dysfunction.

These effects are grouped into System-Organ Classes (SOC), including Nervous System Disorders, Gastrointestinal Disorders, Cardiac Disorders, and Psychiatric Disorders.

Serious Adverse Reactions and Safety Constraints

Regulatory documents explicitly list serious adverse reactions, including the risk of Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-like events, particularly when the medicine is used with other serotonergic agents. Other serious reactions noted include clinically significant sustained blood pressure increases (Hypertension) and Hyponatremia (low sodium levels), which warrants monitoring.

Safety constraints prohibit co-administration with Monoamine Oxidase Inhibitors (MAOIs). Caution is advised for individuals with uncontrolled hypertension or a history of seizures.

Exposure-Related and Population-Specific Notes

Official labeling notes that some adverse reactions, such as nausea and headache, are more frequently observed during the initial phase of treatment or following dose increases. Conversely, effects like sexual dysfunction may be associated with long-term use.

For specific groups, regulatory documents state that dose modifications are generally required for patients with moderate to severe renal or hepatic impairment. Caution is also noted for use in older adults.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Individuals must seek immediate medical attention for any suspected overdose of Venlafaxine. This is a mandatory emergency action stated in official regulatory documents, especially given the documented increased risk of fatal outcomes associated with this overdosage compared to some other antidepressant classes.

Documented Manifestations and Severe Outcomes

Overdosage may present with signs of central nervous system and cardiovascular toxicity. Officially documented clinical manifestations include tachycardia (fast heart rate), mydriasis (pupil dilation), tremor, vomiting, seizures (convulsions), and varying degrees of altered consciousness (from somnolence to coma).

Urgent medical care is required immediately if signs of potentially life-threatening conditions appear. These severe outcomes documented in the label include Serotonin Syndrome, Neuroleptic Malignant Syndrome (NMS)-like reactions, and severe fatal cardiac arrhythmias (such as Torsade de pointes and ventricular fibrillation). Overdose severity may be increased by co-ingestion of alcohol or other medicinal products.

Overdose Management Profile Official Regulatory Statements
Antidote Status No specific antidote is known.
Management Supportive and symptomatic treatment, airway management, and consideration of gastric lavage or activated charcoal.
Monitoring ECG monitoring is explicitly required for observation due to documented cardiovascular risks.
Advertisements

Therapeutic Uses of Венлафаксин

What Венлафаксин treats: Main Uses and Benefits

The use of Venlafaxine is centered on providing supportive therapeutic benefit and symptomatic relief across several key emotional and psychological domains, particularly when symptoms create noticeable interference with daily stability. It is commonly used in conditions that present with disruptive symptom manifestations, including Major Depressive Disorder, Generalized Anxiety Disorder, Social Anxiety Disorder, and Panic Disorder.


Therapeutic Scope

This medicine is commonly used across conditions characterized by periods of heightened symptoms, such as the persistent sadness, hopelessness, and loss of pleasure (anhedonia). It supports patients during episodes of heightened discomfort and contributes to easing the overall symptom load. Venlafaxine is used in areas where short-term symptom management is appropriate for chronic anxiety and acute emotional patterns. It is relevant for managing symptoms that interfere with daily comfort, including excessive worry, high physical tension, and symptoms associated with acute or episodic changes. This assists with maintaining functional stability when symptoms become more noticeable.


Quick Fact: Relief for Mood and Anxiety

Property Description
Symptom Focus Persistent sadness, chronic worry, and acute panic manifestations.
Primary Benefit Helps ease the overall symptom load and provides supportive relief when symptoms interfere with routine activities.

Regulatory References

  1. NIH DailyMed Label for Venlafaxine Extended-Release Capsules
Advertisements

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility Rules

Venlafaxine is officially approved for use in adult patients aged 18 years and older. Use is not approved and not recommended for children and adolescents [Source 1.2].

Category Official Regulatory Status/Statement
Populations for whom use is contraindicated Patients with known hypersensitivity to the drug or its components. Concurrent use with a Monoamine Oxidase Inhibitor (MAOI), including linezolid or intravenous methylene blue [Source 1.2, 1.4].
Age-related eligibility rules Approved for Adults; Not Approved for Pediatric Patients (under 18 years) [Source 1.2]. Older adults (65+) require no specific adjustment based on age alone but should be managed cautiously [Source 2.3].
Condition-specific eligibility rules Renal and Hepatic Impairment: Eligibility is conditional upon a mandatory dose reduction, which can range from 25% to 50% or more for moderate to severe impairment [Source 2.2].
Pregnancy and lactation eligibility Use during Pregnancy is only permitted if clearly needed; third-trimester exposure is associated with risks of poor neonatal adaptation [Source 1.2]. For Lactation, the label advises discontinuing either the drug or nursing [Source 1.2].
Eligibility-related restrictions Use requires caution in patients with a history of seizures or untreated narrow-angle glaucoma risk [Source 1.2, 1.6]. Patients must also be screened for bipolar disorder prior to initiation [Source 1.7].
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Venlafaxine's official interaction profile primarily involves combinations that are either strictly prohibited or require close attention, based on regulatory documentation.

Contraindicated and Restricted Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs), including the antibiotic Linezolid and Intravenous Methylene Blue, is strictly contraindicated. This prohibition is due to the documented risk of Serotonin Syndrome. A mandatory period of at least 14 days must elapse after discontinuing an MAOI before starting Venlafaxine, and at least 7 days must elapse after stopping Venlafaxine before starting an MAOI.

Concomitant use with other serotonergic agents (e.g., Triptans, Tramadol, Lithium) also increases the risk of Serotonin Syndrome.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Substance/Class Official Outcome
Pharmacokinetic CYP2D6 & CYP3A4 Inhibitors Increases the systemic exposure (plasma concentration) of Venlafaxine and/or its active metabolite (ODV).
Pharmacodynamic Drugs that Interfere with Hemostasis (e.g., NSAIDs, Warfarin) Increases the documented risk of abnormal bleeding events.

Co-administration with Haloperidol and Metoprolol officially increases the plasma concentrations of those respective drugs. Additionally, patients using the extended-release formulation are officially advised to avoid alcohol (ethanol), as it can accelerate the rate of drug release.

Advertisements

Mechanism of Action

Dual Reuptake Inhibition of Serotonin and Norepinephrine

Венлафаксин functions as a Serotonin-Norepinephrine Reuptake Inhibitor (SNRI), targeting and blocking the presynaptic Serotonin Transporter (SERT) and the Norepinephrine Transporter (NET). This inhibitory interaction prevents the reabsorption of the neurotransmitters serotonin (5-HT) and norepinephrine (NE) from the synaptic cleft into the neuron, resulting in a significantly increased concentration of both monoamines available for signaling.


Enhanced Monoaminergic Signaling and Systemic Effects

This sustained elevation of 5-HT and NE leads to prolonged stimulation of their respective postsynaptic receptors throughout the central nervous system (CNS). This enhanced signaling induces neuroplastic changes over time, influencing activity within neural circuits and modifying signaling dynamics within circuits linked to affective processing. Furthermore, the mechanism influences regulatory systems by enhancing activity in the descending pain inhibitory pathways, which contributes to altered signal transmission in these regulatory systems.

Advertisements

Dosage and Administration Information

Instruction Map: How to use Venlafaxine — Administration Guidelines

This map details the instructions for the use of Venlafaxine and the required administration patterns.


Administration Scope

Feature Guideline
Route of administration Oral administration only.
Dosing schedule Initial doses start at 37.5 mg/day or 75 mg/day (Extended-Release, XR); maximum dose is typically 225 mg/day. Titration intervals must not be shorter than 4 to 7 days.
Timing in relation to meals Must be taken with food at approximately the same time each day.
Preparation requirements XR tablets or capsules must be swallowed whole and must not be crushed or chewed to preserve the release mechanism.
Population-specific rules Requires dose reduction (25% to 50%) for documented renal or hepatic impairment. Not approved for pediatric patients.
Special conditions Discontinuation requires gradual dose reduction (tapering); missed doses should be skipped entirely, taking the next dose at the scheduled time.

Instruction Classifications (High-Level)

Classification Description
Administration method type Oral (Single oral use).
Frequency pattern Daily (Once daily for XR; divided doses for Immediate-Release).
Basis of use Standard pharmacological parameters.
Use-context constraints Food-dependent administration with mandatory restrictions on crushing the extended-release formulation.

Resulting Procedural Structure

Standard step sequence:

  • Initiate treatment with the specified starting dose, taken once daily with food at a consistent time.
  • Maintain the integrity of the Extended-Release formulation by swallowing it whole, avoiding crushing or chewing.
  • Follow the protocol for gradual dose titration, with increments spaced by the minimum required interval.
  • When discontinuing the long-term course, implement the required process for gradual dose tapering.

Connection to the overall use protocol (2–4 sentences): The instructions establish a structured protocol that governs the initiation of treatment, the required timeline for subsequent dose adjustments, and the process for reduction when discontinuing use. This framework requires adherence to taking the drug with food and preserving the integrity of the extended-release formulation to comply with the established administration parameters.

Advertisements

Recent Clinical Evidence

Recent Clinical Evidence for Venlafaxine

Clinical research on Venlafaxine primarily focuses on its use in treating Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), and Panic Disorder.

Key studies have investigated its therapeutic action, which relates to the balanced reuptake inhibition of both serotonin and norepinephrine in the central nervous system.

Study Designs and Key Findings

Most evidence stems from randomized, controlled trials (RCTs) and systematic reviews. These studies are designed to compare the drug's effect against a placebo or an active comparator over defined treatment periods.

  • Efficacy in MDD: Studies consistently investigated whether the drug's use correlated with a reduction in symptom severity scores, as measured by standardized scales (e.g., HAM-D or MADRS). Research has explored whether participants demonstrated remission (a return to a near symptom-free state) and a reduction in relapse rates over long-term maintenance phases.
  • Anxiety Disorders: RCTs evaluated the drug's effect on both psychic and somatic symptoms of GAD and Panic Disorder. Findings were assessed via validated scales, focusing on whether a decrease in the frequency and severity of anxiety and panic attacks was observed in the study populations.

Comparative and Long-Term Research

Comparative studies have assessed the drug's activity against other treatments, including selective serotonin reuptake inhibitors (SSRIs) and other non-pharmacological interventions. These comparisons examine specific endpoints such as tolerability, time to response, and rates of treatment discontinuation.

Long-term maintenance studies monitored participants for six months to one year to determine if initial benefits were sustained and to gather data on the incidence of adverse events over prolonged exposure. These trials are critical for understanding the drug's performance beyond the initial acute phase of treatment.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Венлафаксин (FAQ)


Q: What is Venlafaxine prescribed for besides depression?

According to official regulatory documents, Venlafaxine is approved to treat Major Depressive Disorder, Generalized Anxiety Disorder, Social Anxiety Disorder (Social Phobia), and Panic Disorder. These are the main conditions for which the medication has established efficacy in clinical studies.


Q: How is Venlafaxine different from other popular antidepressants, such as Fluoxetine?

Venlafaxine is classified as a Serotonin-Norepinephrine Reuptake Inhibitor (SNRI). Its mechanism of action involves strongly inhibiting the reuptake of both serotonin and norepinephrine in the central nervous system. This dual action is the primary distinction, as most popular antidepressants primarily affect the reuptake of serotonin only.


Q: Can taking Venlafaxine cause sleep problems?

Official product information documents that sleep disturbances are recognized adverse effects of Venlafaxine. This includes common issues such as insomnia (difficulty sleeping), somnolence (drowsiness), and experiencing unusual dreams.


Q: Can Venlafaxine cause weight gain or weight loss?

Official reports indicate that Venlafaxine can cause changes in appetite and consequently, changes in body weight. In clinical trials, both decreased and increased body weight have been observed among users.


Q: Is there a difference between the Extended-Release (XR) capsules and the regular tablets of Venlafaxine?

Yes, there is a difference in administration. The Extended-Release (XR) capsules are intended to be taken once daily to allow for a slow release of the medication over the course of the day. In contrast, the immediate-release (IR) tablets are typically taken in divided doses throughout the day.


Q: Does Venlafaxine affect libido or sexual function?

Sexual dysfunction is a documented and common adverse reaction associated with Venlafaxine. These effects can include decreased libido (sex drive), difficulty achieving orgasm, and in males, problems with erection and ejaculation. Patients should be informed about this potential effect.


Q: What should I do if I miss a dose of Venlafaxine?

Regulatory guidance suggests that if a dose is missed, it can be taken as soon as it is remembered, unless it is close to the time of the next scheduled dose. Two doses must not be taken together to compensate for the missed dose. For specific dose management, patients must follow the directions provided by their prescriber.


Q: Is Venlafaxine prescribed for Generalized Anxiety Disorder?

Yes, regulatory documents confirm that Venlafaxine is an approved treatment for Generalized Anxiety Disorder (GAD) in adults.


Q: Can Venlafaxine help with panic attacks?

Yes. According to official indications, Venlafaxine is approved for the treatment of Panic Disorder, with or without agoraphobia.


Q: Why can some people who have not responded to SSRIs be prescribed Venlafaxine?

This is due to its dual mechanism of action as a Serotonin-Norepinephrine Reuptake Inhibitor (SNRI). This mechanism involves the inhibition of norepinephrine reuptake in addition to serotonin. This dual action is thought to provide a different pharmacological approach when a patient does not respond adequately to a Selective Serotonin Reuptake Inhibitor (SSRI).


Q: Is Venlafaxine an original drug or a generic?

Venlafaxine is the generic name for the active substance. It is available under various brand names, including the original brand (Effexor®), as well as multiple generic versions. The availability of generics is confirmed by official drug databases.


Q: Why is Venlafaxine sometimes called a 'dual' antidepressant?

Venlafaxine is referred to as a 'dual' antidepressant because its mechanism of action is related to the inhibition of the reuptake of two key neurotransmitters in the brain: serotonin and norepinephrine. This dual effect differentiates it from many antidepressants that influence only serotonin.


Q: Do I need to follow a special diet while taking Venlafaxine?

A strict diet is not generally required. However, official administration instructions specify that the medication should be taken with food. Additionally, patients taking the extended-release formulation are officially advised to avoid consuming alcohol, as it can accelerate drug release.


Q: Does Venlafaxine help with chronic pain?

Chronic pain is not an officially approved indication for Venlafaxine in major regulatory regions. Although not an approved use, the drug’s mechanism of affecting neurotransmitters like norepinephrine can influence neural pathways associated with pain signaling.


Q: Can Venlafaxine worsen memory or concentration?

Documented side effects include phenomena such as attention disturbance, confusion, and memory impairment. This indicates a potential for the medication to affect cognitive functions, according to official adverse reaction reports.


Q: Are there contraindications for taking Venlafaxine for people with glaucoma?

Yes. Venlafaxine is formally contraindicated in patients with uncontrolled angle-closure glaucoma. This restriction is due to the potential risk of pupillary dilation, which could precipitate an acute glaucoma attack.


Q: What is the difference between Velaxin, Velafax, and other trade names for Venlafaxine?

Velaxin, Velafax, and other names are trade names (brands) for medications containing the active substance Venlafaxine. Differences primarily relate to the specific manufacturer, the formulation (IR/XR), and the country where the drug is marketed.


Q: Do I need to take Venlafaxine at the same time every day?

Official administration guidance recommends that Venlafaxine be taken at approximately the same time each day. This practice is important for maintaining a consistent concentration of the drug in the bloodstream, which is critical for extended-release formulations.


Q: Is it safe to take Venlafaxine for a long time (years)?

The effectiveness of Venlafaxine has been established through long-term maintenance studies, typically involving observation periods of up to one year. Long-term use extending beyond the studied maintenance periods requires continuous evaluation by a prescribing professional.


Q: Why do doctors sometimes prescribe Venlafaxine in very low doses?

Regulatory information and the mechanism of action suggest a dose-related difference in effect. Lower doses may achieve a primarily serotonergic effect, while higher doses introduce a more pronounced noradrenergic action. Starting with low doses also helps to manage potential initial side effects.


Q: Is it possible to become dependent on Venlafaxine?

Venlafaxine is not classified as a controlled substance and does not typically cause addiction. However, abrupt cessation can lead to a discontinuation syndrome (symptoms of withdrawal). A gradual dose reduction (tapering) is officially recommended upon discontinuation to minimize these effects.


Q: What are the main approved indications for Venlafaxine?

The officially approved indications include Major Depressive Disorder, Generalized Anxiety Disorder, Social Anxiety Disorder (Social Phobia), and Panic Disorder.


Q: Is it possible to overdose on Venlafaxine?

Yes, overdose is possible with Venlafaxine. Official information on overdosage describes potential symptoms such as drowsiness, rapid heart rate, seizures, and vomiting. Symptoms of overdose require immediate medical evaluation.


Q: Does the Venlafaxine prescribing information mention the need for ECG monitoring?

Official information warns of the risk of sustained increases in blood pressure and changes in heart rate, which may necessitate blood pressure monitoring. The necessity of specific cardiac monitoring (like an ECG) is determined by the prescriber based on the individual patient’s overall cardiovascular health.


Q: How does Venlafaxine affect cognitive functions?

Based on documented side effects, Venlafaxine can affect cognitive functions. Adverse reactions that have been reported include impaired attention, problems with concentration, and states of confusion.


Q: How long after starting Venlafaxine does it start to take effect?

While regulatory labels do not specify a precise onset time, clinical guidelines generally note that initial symptomatic improvements may be observed within 1 to 2 weeks. However, the full therapeutic benefit usually requires approximately 4 to 6 weeks of consistent treatment.


Q: How long is Venlafaxine usually taken to achieve its full effect?

Clinical studies for major depression typically assess the acute treatment period over 8 to 12 weeks. Once a response is achieved, treatment is often continued for a maintenance period of 6 months or longer to help prevent symptoms from returning (relapse).


Q: Is it difficult to stop taking Venlafaxine, and what are the withdrawal symptoms?

Stopping the medication abruptly can induce a discontinuation syndrome (symptoms of withdrawal). Documented symptoms can include irritability, nausea, dizziness, vomiting, nightmares, and paresthesias (sensations described as tingling or 'brain zaps'). A gradual dose reduction (tapering) is officially recommended to minimize these effects.


Q: What does 'discontinuation syndrome' mean when stopping Venlafaxine?

Discontinuation syndrome refers to a cluster of physical and psychological symptoms that may occur when a drug affecting brain chemistry is stopped or reduced too quickly. For Venlafaxine, symptoms include headache, vomiting, dizziness, sleep disturbances, and a sensation of tingling or electric shocks.


Q: How long do Venlafaxine side effects usually last after starting treatment?

Official information indicates that many common side effects, such as nausea and headache, are typically observed in the initial phase of treatment or following dose increases. These effects generally tend to lessen over time as the body adjusts to the medication.


Q: Is there a risk of suicidal thoughts when starting Venlafaxine, especially in young people?

Yes. The product carries a Boxed Warning regarding an increased risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (up to age 24) compared to placebo in short-term studies. Regulatory guidelines emphasize the need for close monitoring during the initial phases of treatment or dose changes, especially in these age groups.


Q: What symptoms indicate that Venlafaxine may not be suitable?

Serious symptoms such as signs of Serotonin Syndrome (e.g., severe agitation, rapid heart rate, hallucinations), a severe increase in blood pressure, or new/worsening suicidal thoughts require prompt medical evaluation. The prescribing professional can offer guidance on symptoms that may indicate the drug is not appropriate.


Q: What precautions should be taken when driving a car while on Venlafaxine?

Due to the potential for drowsiness or impaired judgment, regulatory warnings caution against driving, operating heavy machinery, or engaging in hazardous activities until the individual understands the medication’s effects on their own reaction time and abilities.


Q: Can Venlafaxine be taken during pregnancy or breastfeeding?

Official information states that use during pregnancy may be associated with complications, such as neonatal adaptation syndrome in newborns. The drug and its active metabolite pass into breast milk. The use of Venlafaxine during pregnancy or breastfeeding requires a careful evaluation of the potential benefits versus the risks to the infant or fetus by a healthcare professional.


Q: What tests or examinations might be required before starting Venlafaxine?

Official warnings recommend that blood pressure monitoring should be performed before starting treatment and regularly during therapy, as the drug can cause sustained hypertension. Testing of kidney and liver function may also be considered, as regulatory information indicates that dose adjustments are necessary for patients with known impairment in these areas.

Advertisements

How should Венлафаксин be stored and disposed of?

Storage and Disposal of Venlafaxine

Required Storage Conditions

Venlafaxine must be stored at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F), with temporary excursions permitted between 15 C and 30 C. The product must be kept in its original container, and the container must be tightly closed to protect it from moisture. A mandatory regulatory requirement is to keep the medication out of the sight and reach of children.


Official Disposal Instructions

Venlafaxine is not recommended for disposal by flushing down the toilet. The preferred method for discarding unused or expired product is via an authorized drug take-back program. If a take-back program is unavailable, the medication may be disposed of in the household trash after mixing it with an unappealing substance, such as dirt or used coffee grounds, and sealing it in a container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Венлафаксин found in:

A-Z Index: